The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Predictive value of BRCA1, ERCC1, ATP7B, PKM2, TOPO-I, TOPO-iia, TOPO-iib, and c-MYC genes in patients with small cell lung cancer (SCLC) who received first-line therapy with cisplatin and etoposide.
Chara Papadaki
No relevant relationships to disclose
Niki Karachaliou
No relevant relationships to disclose
Eleni Lagoudaki
No relevant relationships to disclose
Maria Trypaki
No relevant relationships to disclose
Maria Sfakianaki
No relevant relationships to disclose
Anastasios Koutsopoulos
No relevant relationships to disclose
Dimitrios Mavroudis
No relevant relationships to disclose
Efstathios Stathopoulos
No relevant relationships to disclose
Vassilis Georgoulias
No relevant relationships to disclose
John Souglakos
No relevant relationships to disclose